FCT PhD Programme i3DU
Course Molecular Biomarkers and Technologies 2019

8 July 2019
9:00 am

5 days
Faculdade de Farmácia, Universidade de Lisboa
Amphiteater B

The course on Molecular Biomarkers and Technologies is part of the PhD Programme in Medicines and Pharmaceutical Innovation (i3DU), trains students in the development of advanced medicinal products, covering crucial aspects that determine the fate of drugs in the human or animal body, from their fundamentals to the advanced strategies to overcome the physiological barriers, including innovative technological and therapeutic applications.

The course will be held at the Research Institute for Medicines (iMed.ULisboa), Faculdade de Farmácia, Universidade de Lisboa, in Lisbon, 08-12 July, 2019. The training program is aimed at PhD students, but welcomes the participation of external academic and scientific community members. Registration is free but mandatory.

Course outline

Biomarkers are now an integral part of the drug discovery and development process, acting as indicators of mechanism of action, efficacy, safety and disease progression, as well as assisting in disease diagnosis, patient selection and clinical trial design. Biomarkers also offer the potential to inform treatment decisions and bring personalized medicine into clinical practice.

In early stage drug discovery, biomarkers are used to validate target engagement and modulation. As projects progress, biomarker assays are developed for pharmacokinetic/pharmacodynamic (PK/PD) models, profiling molecules prior to testing in disease models as initial proof of concept. PK/PD models can also assist in dose-to-man scaling predictions for use in clinical trials. Importantly, the biomarker assays developed during the in vitro discovery phases are frequently used as efficacy or toxicity endpoints in the clinic. Clinical trials, particularly in oncology, are frequently designed around these biomarkers, in addition to biomarkers of disease progression.

Special focus is also given to the development, robust validation and advancement in technologies towards biomarkers that diagnose, risk stratify and/or monitor disease progression.